Best Weight Loss Pills for 2026: FDA Approves First Oral GLP-1 and What It Means for Patients
UOG (United One Group) Wins Three Prestigious Industry Awards at CES 2026
Best Ipamorelin vs Sermorelin: Growth Hormone Peptide Comparison 2026 — ReadyRx Prescription Telehealth Analysis
GLP-1 Booster From Health Journey: 2026 Ingredient Analysis And Probiotic Metabolic Support Explained
MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs
ASCEND comprises two dosing regimens of certepetide evaluated in two separate study arms enrolled sequentially Positive signal in progression-free survival...
MALVERN, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical...
Recognition highlights EluPro™ Antibiotic-Eluting BioEnvelope’s impact on device protection for cardiac implantable electronic devices (CIEDs) and neurostimulators SILVER SPRING, Md.,...
GREENWOOD VILLAGE, Colo., June 26, 2025 (GLOBE NEWSWIRE) -- Pure Harvest Corporate Group, Inc. (OTC: PHCG), a strategic holding company...
Certification demonstrates Liviniti's strong commitment to data security and risk managementNatchitoches, Louisiana--(Newsfile Corp. - June 26, 2025) - Liviniti, a...
Calgary, Alberta--(Newsfile Corp. - June 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")...
London, United Kingdom--(Newsfile Corp. - June 26, 2025) - Edison issues report on Lamda Development (ASE: LAMDA).LAMDA Development is the...
The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adults with...
Company in full compliance for continued listingMIRAMAR, Fla., June 26, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the...
Initiation of patient recruitment marks a key milestone in the development of VAR 200, a potential first-in-class treatment for kidney...
PALO ALTO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new...
UNIONDALE, NY, June 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation...
U.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated...
Attractive safety profile demonstrated across all dosing cohorts and routes of administration (IV, SC, and IM); all reported adverse events...
First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with...
-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with...
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, June 26,...
Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in...
TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a...
New Study Provides Insight into the Bioavailability of Medical Cannabis Formulations for Therapeutic TreatmentNEW YORK, June 26, 2025 (GLOBE NEWSWIRE)...
